GRI VS PRFX Stock Comparison

Performance

GRI
10/100

GRI returned -91.59% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.

PRFX
10/100

PRFX returned -59.09% in the last 12 months. Based on SPY's performance of -12.95%, its performance is below average giving it a score of 10 of 100.

Profit

GRI
20/100

Out of the last 4 quarters, GRI has had 1 profitable quarters and has increased their profits year over year on 0 of them.

PRFX
10/100

Out of the last 18 quarters, PRFX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

GRI
36/100

GRI has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

PRFX
100/100

PRFX has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.

Technicals

GRI

"Technicals" not found for GRI

PRFX
39/100

PRFX receives a 39 of 100 based on 14 indicators. 5 are bullish, 8 are bearish.

Earnings

GRI

"Earnings" not found for GRI

PRFX
10/100

PRFX has missed earnings 5 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

GRI Bio, Inc. Common Stock Summary

Nasdaq / GRI

Healthcare

Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

PainReform Ltd. Ordinary Shares Summary

Nasdaq / PRFX

Healthcare

Drug Manufacturers - Specialty & Generic

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Power up your portfolio